Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/78399
Título
Interventions for submacular haemorrhage: A systematic review and network meta‐analysis of controversies—On behalf of the Spanish Vitreo‐Retinal Society (SERV)
Autor
Año del Documento
2025
Editorial
Wiley
Descripción
Producción Científica
Documento Fuente
Acta Ophthalmologica, 2025, p. 1-25
Zusammenfassung
Purpose
This systematic review aims to evaluate and synthesize the existing literature on the interventions used for submacular haemorrhage (SMH), highlighting the controversies and differences in clinical practice.
Method
A systematic review was conducted following the PRISMA guidelines. A comprehensive search was performed across multiple databases, including MEDLINE, EMBASE and Cochrane Library, to identify studies on SMH treatment. Inclusion criteria encompassed randomized controlled trials, cohort studies and case series that focused on different therapeutic interventions. Data on functional outcomes, efficacy and safety of the interventions were extracted and analysed.
Results
The review included 150 studies, of which 38 were included in the network meta-analysis. The analysis of best corrected visual acuity (BCVA) Included 26 studies, 20 interventions and 2125 eyes. Heterogeneity was moderate (I2 = 28.9%). Non-vitrectomy therapies showed better BCVA outcomes and fewer complications (e.g. retinal detachment, vitreous haemorrhage), while vitrectomy-based treatments achieved better anatomical results. According to P-score ranking, “Observation” had the highest probability of being most effective for BCVA (P-score = 0.8051), followed by anti-VEGF monotherapy and non-vitrectomy combinations. However, this result should be interpreted cautiously, as the “Observation” group was based on only two studies (26 eyes) with clinical heterogeneity. No publication bias was detected (Egger's test p = 0.582).
Conclusions
There is no consensus on a standard evidence-based treatment for SMH. Minimally invasive strategies are promising, but factors such as timing, lesion size and anti-VEGF use remain critical. Further large-scale randomised trials are needed to define optimal management.
Materias (normalizadas)
Degeneración macular relacionada con la edad
Factor de crecimiento endotelial antivascular
Vitrectomía pars plana
Desplazamiento neumático
Vasculopatía coroidea polipoide
Hemorragia submacular
Hemorragia subretiniana
Activador tisular del plasminógeno
ISSN
1755-375X
Revisión por pares
SI
Patrocinador
Open access funding provided by FEDER European Funds and the Junta De Castilla y León under the Research and Innovation Strategy for Smart Specialization (RIS3) of Castilla y León 2021-2027.
Version del Editor
Propietario de los Derechos
© 2025 The Author(s)
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Aparece en las colecciones
Dateien zu dieser Ressource
